Plain-English translation of NCT07419295 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called to treat advanced bladder cancer that has gotten worse despite previous treatments. Researchers want to know if this medication helps people live longer than standard chemotherapy drugs like , , or . The medication works by targeting cancer cells in a specific way that chemotherapy alone does not.
Bladder cancer that has spread or is locally advanced often comes back even after chemotherapy, immunotherapy, and other treatments. Doctors need new options to help patients whose cancer is no longer responding to standard care, and this trial is testing whether this medication can offer better results.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication (given as an intravenous infusion every 2 weeks) or one of three standard chemotherapy options (given every 3 weeks), as chosen by your doctor. You will continue receiving your assigned treatment until your cancer gets worse or you experience side effects that are too difficult to manage. Throughout the trial, you will have regular visits for blood tests, scans, and check-ups to monitor how you are doing and how your cancer is responding.
AI-generated summary from trial data · Sep 2, 2026 · Not medical advice
United States